Drug intelligence / Profile preview

Precision Cell Immunotherapy

Development stage: Phase 2
Lead developer: Ningbo Cancer Hospital
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies

Overview

Precision Cell Immunotherapy is a cell therapy designed to treat advanced gastric cancer. It involves the administration of two types of cell suspensions: DC cell suspension and PNAT/PMAT cell suspension. The DC cell suspension contains 1x10^7 DC cells combined with physiological saline and 0.25% human blood albumin, administered subcutaneously. The PNAT/PMAT cell suspension contains 1-6x10^9 PNAT cells, also combined with physiological saline and 0.25% human blood albumin, administered intravenously. This therapy is being evaluated for its safety and effectiveness in patients with advanced gastric cancer.

Other names: Precision CellsDC-PMAT-PNAT therapyPrecision Cell therapy

Beyond the preview

Go deeper on Precision Cell Immunotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Cell Immunotherapy.

Explore the full profile